HeadSense Engages Sage to Deliver Global Demand Forecast

International go-to-market research completed for revolutionary medical device

Baltimore, MD – June 10, 2015 · Sage Growth Partners (SGP), a Baltimore-based healthcare consulting, technology and marketing firm today announced the successful completion of an international go-to-market research project for HeadSense Medical Inc.

HeadSense is an early stage company developing a non-invasive neurological monitor focused initially on an intracranial pressure (ICP) application. Financed by GE Ventures (Menlo Park, CA), Pontifax, a leading Israeli VC, and investment groups, Everett Partners (Akron, OH) and JuMaJo (Hamburg, Germany), HeadSense is aggressively expanding its revolutionary work by bringing to market its non-invasive ICP monitor.

With promising clinical trial results, HeadSense selected SGP to deliver a five-year global demand forecast to guide commercialization strategy and activities. To effectively execute the analysis, SGP studied three clinical use cases — stroke, traumatic brain injury (TBI), and brain tumors — to create an incidence rate for each diagnosis in each country analyzed. Sage selected eleven countries and five regions, defined the addressable markets in each, and determined country-specific sales forecasts.

“Forecasting global demand for HeadSense’s revolutionary device was a complicated process,” said Sage Growth COO, Dan D’Orazio. “We couldn’t just go find a number. Each of the countries had a widely diverse level of available data.”

In addition to the challenges presented by a lack of uniform data sets, the SGP team researched and analyzed country-specific populations, how healthcare is delivered in each, how it is funded, the health economy of each country, and the impact on supply and demand.

Of the successful go-to-market global research project for Headsense, D’Orazio added, “I think the beauty of this work is the translational aspect. We delivered heavily researched, carefully fact-checked data and then translated that data into a market demand forecast for HeadSense. Research is a great skill, but you have to be able to convert data and insights into actionable market information. We believe we do this very well and that it provides big benefits to our clients.”

Guy Weinberg, CEO of HeadSense says of SGP’s work, “Because of the outstanding work from Sage Growth, we are an important step closer to bringing our technology to market. We firmly believe we have a disruptive health innovation that can play a crucial role in improving the quality and affordability of healthcare on a global scale. Sage was the right partner to deliver this work.”

About Headsense

HeadSense Medical Ltd. is an innovative young company with a mission to develop disruptive products that will allow physicians and patients to diagnose and monitor clinical parameters in an easier and cost-effective way. The company is focusing on agile platforms with automated proprietary algorithms that diagnose and monitor various clinical parameters and conditions. HeadSense’s first product, the HS-1000, is a non-invasive ICP monitor offering accurate and continuous ICP monitoring. The product has been clinically validated in multiple clinical trials worldwide, and has received CE approval.


About Sage Growth Partners

Sage Growth Partners (SGP), a healthcare strategy, technology and marketing firm, provides insight, advice and multi-disciplined execution to growth-minded healthcare organizations nationally, including hospitals, health systems, physicians groups, insurers, trade associations and academic institutions. With deep roots in the business of healthcare, SGP delivers results to difficult industry and organizational challenges.

Founded in 2005, SGP is located in Baltimore, MD and serves clients such as GE Healthcare, Boston Scientific, SAS, Stericycle, Availity and HeartFlow.

Download release